Laquinimod for MS misses primary endpoint in BRAVO trial
Posted: Mon Aug 01, 2011 5:30 am
Teva Pharmaceutical Industries Ltd. and Active Biotech announced today initial results from the Phase III BRAVO study, which was designed to evaluate the efficacy, safety and tolerability of oral laquinimod compared to placebo and to provide a benefit-risk assessment comparing oral laquinimod BRAVO is the second of two pivotal Phase III studies in the clinical development program for laquinimod, an investigational, oral, once-daily therapy for the treatment of relapsing-remitting multiple sclerosis (RRMS). Results showed that the BRAVO study did not achieve its primary endpoint of reducing the annualized relapse rate (p=0.075).... Read More - http://www.msrc.co.uk/index.cfm/fuseact ... ageid/1735